Perindopril Tablets

Perindopril is an inhibitor of the enzyme (angiotensin converting enzyme) that converts angiotensin I to angiotensin II. This converting enzyme or kinase is an exopeptidase that converts angiotensin I to the vasoconstrictor angiotensin II. It also degrades the vasodilator bradykinin to an inactive heptapeptide. Inhibition of angiotensin converting enzyme results in a decrease in angiotensin II in the plasma, which can lead to an increase in plasma renin activity (by inhibiting the negative feedback effect of renin release) and a decrease in aldosterone secretion. Because angiotensin converting enzyme inactivates bradykinin, angiotensin converting enzyme inhibition can also increase the activity of the circulating and local kallikrein-kinin system (and thus the prostaglandin system).

Perindopril tert-butylamine salt

This product is a green round tablet with scores on both sides.

Hypertension and congestive heart failure.

Perindopril tablets must be taken before meals because food changes the bioavailability of its active metabolite perindoprilat. Perindopril is taken once a day. 1. Anhydrous sodium loss or renal failure (i.e. under normal circumstances): The effective dose is 4 mg/day, taken once in the morning. Depending on the efficacy, the dose can be gradually increased to a maximum dose of 8 mg/day within three to four weeks. If necessary, potassium-excreting diuretics can be used in combination to further lower blood pressure. 2. Hypertensive patients who have been treated with diuretics: (1) Stop taking diuretics three days before starting treatment. If necessary, diuretics can be added again later. (2) Or start treatment with 2 mg and adjust the dose according to the antihypertensive effect. It is recommended to monitor blood creatinine and blood potassium levels before treatment and within the first 15 days of treatment. 3. Elderly people (see

1. Headache, fatigue, dizziness, mood or sleep disorders, cramps; 2. Postural or non-postural blood pressure (see: Precautions); 3. Rashes in a few cases; 4. Stomach pain, anorexia, nausea, abdominal pain, taste disorders; 5. Dry cough has been reported to be associated with the use of ACE inhibitors, which is characterized by persistence, but the dry cough disappears after discontinuation of the drug. If the above situation occurs, it should be considered that this symptom may be caused by the drug; 6. Very rare: angioedema (see: Warnings) affects laboratory indicators; 7. Moderate increase in blood urea and blood creatinine, which can be restored after stopping treatment. This increase is more common in patients with hypertension and renal failure with combined renal artery stenosis, diuretic treatment; 8. In patients with glomerular nephropathy, ACE inhibitors can cause proteinuria; 9. Hyperkalemia, usually transient; 10. Anemia (see: Precautions) has been reported to occur in special patients (renal transplantation, hemodialysis) treated with ACE inhibitors.

1. Perindopril is contraindicated in the following cases: ① Allergy to perindopril; ② History of angioedema associated with the use of ACE inhibitors; ③ 4 to 9 months of pregnancy; ④. Breastfeeding. 2. Perindopril is not recommended in the following cases: ① Combined use with potassium-sparing diuretics, potassium salts, lithium salts, and estradiol nitrogen mustard; ② Bilateral renal artery stenosis or unilateral renal artery stenosis; ③ Hyperkalemia; ④ In the first three months of pregnancy and breastfeeding.

Precautions for children: The safety and efficacy of perindopril in children have not been determined. Precautions for pregnancy and lactation: Pregnancy: No teratogenicity has been reported in animal experiments, but embryotoxicity has been found in several species. In clinical trials: 1. No epidemiological studies 2. No congenital malformations have been found in individual pregnant women who took ACE inhibitors in the first three months of pregnancy. 3. During the 4th to 9th months of pregnancy, especially until delivery, pregnant women who take ACE inhibitors are at risk of renal damage, which is manifested as: 3.1 Reduced fetal renal function and may be accompanied by oligohydramnios 3.2 Neonatal renal failure with hypotension and hyperkalemia or even anuria (reversible or irreversible) 4. There have been a few reports of cranial vault malformations when ACE inhibitors are taken throughout pregnancy. Therefore: The risk of drug-induced malformations is low. In cases where pregnancy is accidentally discovered during treatment, it is not necessary to terminate the pregnancy. However, B-ultrasound should be performed to monitor the development of the cranial vault. On the other hand, if a woman is found to be pregnant while taking ACE inhibitors, she must stop taking the medication and not take it again during the entire pregnancy. Perindopril is contraindicated during the 4th to 9th months of pregnancy. Breastfeeding: Due to the lack of information on the drug entering breast milk, breastfeeding mothers are prohibited from taking perindopril. Elderly precautions: Before starting treatment, renal function and blood potassium should be checked (see: Dosage and Administration). The initial dose should be adjusted according to blood pressure changes, and in cases of water and sodium loss, more caution should be exercised to avoid a sudden drop in blood pressure.

1 Potassium-sparing diuretics (spironolactone, triamterene, alone or in combination), except for the treatment of heart failure (low-dose ACE inhibitors with potassium-sparing diuretics), potassium salts, hyperkalemia (can be fatal, especially in cases of renal failure, the drugs have a synergistic effect on the increase in blood potassium). Except for patients with hypokalemia, do not use potassium supplements or potassium-sparing diuretics with ACE inhibitors. 2 Lithium: ACE inhibitors increase blood lithium concentrations even to toxic levels (reduce renal excretion of lithium). If ACE inhibitors must be used, blood lithium levels must be closely monitored and the dose adjusted. 3 Estradiol mustard: Increased risk of angioedema.

seal.

4 mg

24 months.